Plain-English translation of NCT06926790 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two immunotherapy drugs called nivolumab and ipilimumab given before surgery for people with early-stage non-small cell lung cancer. These medications work by helping your immune system recognize and fight cancer cells. The goal is to shrink the tumor before surgery and improve outcomes for patients whose tumors don't have high levels of a specific protein called PD-L1.
While immunotherapy has shown promise in treating advanced lung cancer, doctors want to know if this specific two-drug combination is safe and effective when given before surgery in earlier-stage disease. This approach may be better than traditional chemotherapy, especially for older patients or those whose cancers don't respond well to standard treatments.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the two immunotherapy medications over 6 to 9 weeks (2 to 3 treatment cycles, with each drug given on its own schedule). Between treatments, you'll have imaging scans (CT scans) to monitor how your tumor is responding. After the medication treatments are complete, you would have surgery within 4 to 6 weeks to remove the tumor. Your doctors will monitor you closely throughout for any side effects or complications.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China